The structural basis for control of eukaryotic protein kinases

Annual Review of Biochemistry

Volumn 81, Issue , 2012, Pages 587-613

  Endicott, Jane A ^a   Noble, Martin E M ^a   Johnson, Louise N ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

dimerization; phosphorylation; pseudokinases; signal transduction; substrate recognition

Indexed keywords

ADENOSINE TRIPHOSPHATE; PROTEIN KINASE; SCAFFOLD PROTEIN;

ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; EUKARYOTE; HUMAN; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANIMALS; CATALYTIC DOMAIN; ENZYME ACTIVATION; EUKARYOTA; HUMANS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY;

EUKARYOTA;

EID: 84861859600     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-052410-090317     Document Type: Article

References (139)

1. Brognard J, HunterT. 2011. Protein kinase signaling networks in cancer. Curr. Opin. Genet. Dev. 21:4-11
2. Cohen P. 2002. The origins of protein phosphorylation. Nat. Cell Biol. 4:E127-30
3. Dar AC, Shokat KM. 2011. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. 80:769-95
4. Johnson LN. 2009. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 42:1-40
5. Zhang J, Yang PL, Gray NS. 2009. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9:28-39
6. Johnson LN, Lewis RJ. 2001. Structural basis for control by phosphorylation. Chem. Rev. 101:2209-42
7. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-34
8. MartinDM, Miranda-Saavedra D, Barton GJ. 2009. Kinomer v. 1.0: a database of systematically classified eukaryotic protein kinases. Nucleic Acids Res. 37:D244-50
9. Eswaran J, Knapp S. 2010. Insights into protein kinase regulation and inhibition by large scale structural comparison. Biochim. Biophys. Acta 1804:429-32
10. Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, et al. 1991. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253:407-14
11. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. 1993. Crystal structure of cyclin-dependent kinase 2. Nature 363:595-602
12. Huse M, Kuriyan J. 2002. The conformational plasticity of protein kinases. Cell 109:275-82
13. Nolen B, Taylor S, Ghosh G. 2004. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15:661-75
14. Eswaran J, Bernad A, Ligos JM, Guinea B, Debreczeni JE, et al. 2008. Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture. Structure 16:115-24
15. Eswaran J, Patnaik D, Filippakopoulos P, Wang F, Stein RL, et al. 2009. Structure and functional characterization of the atypical human kinase haspin. Proc. Natl. Acad. Sci. USA 106:20198-203
16. Kornev AP, Haste NM, Taylor SS, Eyck LF. 2006. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. USA 103:17783-88
17. Kornev AP, Taylor SS, Ten Eyck LF. 2008. A helix scaffold for the assembly of active protein kinases. Proc. Natl. Acad. Sci. USA 105:14377-82
18. Ten Eyck LF, Taylor SS, Kornev AP. 2008. Conserved spatial patterns across the protein kinase family. Biochim. Biophys. Acta 1784:238-43
19. Noble ME, Endicott JA, Johnson LN. 2004. Protein kinase inhibitors: insights into drug design from structure. Science 303:1800-5
20. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. 2011. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol. Cell 42:9-22
21. Iakoucheva LM, Radivojac P, BrownCJ, O'ConnorTR, Sikes JG, et al. 2004. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res. 32:1037-49
22. Lowe ED, Noble ME, Skamnaki VT, Oikonomakos NG, Owen DJ, Johnson LN. 1997. The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J. 16:6646-58
23. Goldsmith EJ, Akella R, Min X, Zhou T, Humphreys JM. 2007. Substrate and docking interactions in serine/threonine protein kinases. Chem. Rev. 107:5065-81
24. Cheng KY, Noble ME, Skamnaki V, Brown NR, Lowe ED, et al. 2006. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition. J. Biol. Chem. 281:23167-79
25. Lowery DM, Lim D, Yaffe MB. 2005. Structure and function of Polo-like kinases. Oncogene 24:248-59
26. Komander D, Garg R, Wan PT, Ridley AJ, Barford D. 2008. Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure. EMBO J. 27:3175-85
27. Dar AC, Dever TE, Sicheri F. 2005. Higher-order substrate recognition of eIF2alpha by the RNAdependent protein kinase PKR. Cell 122:887-900
28. Levinson NM, Seeliger MA, Cole PA, Kuriyan J. 2008. Structural basis for the recognition of c-Src by its inactivator Csk. Cell 134:124-34
29. Kim C, Xuong NH, Taylor SS. 2005. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science 307:690-96
30. Song H, Hanlon N, Brown NR, Noble ME, Johnson LN, Barford D. 2001. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phospho-CDK2. Mol. Cell 7:615-26
31. DeyM, Velyvis A, Li JJ, Chiu E, Chiovitti D, et al. 2011. Requirement for kinase-induced conformational change in eukaryotic initiation factor 2alpha (eIF2alpha) restricts phosphorylation of Ser51. Proc. Natl. Acad. Sci. USA 108:4316-21
32. Skamnaki VT, Owen DJ, NobleME, Lowe ED, Lowe G, et al. 1999. Catalytic mechanism of phosphorylase kinase probed by mutational studies. Biochemistry 38:14718-30
33. Stockbridge RB, Wolfenden R. 2009. The intrinsic reactivity of ATP and the catalytic proficiencies of kinases acting on glucose, N-acetylgalactosamine, and homoserine: a thermodynamic analysis. J. Biol. Chem. 284:22747-57
34. Adams JA. 2001. Kinetic and catalytic mechanisms of protein kinases. Chem. Rev. 101:2271-90
35. Grant BD, Adams JA. 1996. Pre-steady-state kinetic analysis of cAMP-dependent protein kinase using rapid quench flow techniques. Biochemistry 35:2022-29
36. Madhusudan, Akamine P, Xuong NH, Taylor SS. 2002. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat. Struct. Biol. 9:273-77
37. Lassila JK, Zalatan JG, Herschlag D. 2011. Biological phosphoryl-transfer reactions: understanding mechanism and catalysis. Annu. Rev. Biochem. 80:669-702
38. BaoZQ, JacobsenDM, YoungMA. 2011. Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis. Structure 19:675-90
39. Cook A, Lowe ED, Chrysina ED, Skamnaki VT, Oikonomakos NG, Johnson LN. 2002. Structural studies on phospho-CDK2/cyclin A bound to nitrate, a transition state analogue: implications for the protein kinase mechanism. Biochemistry 41:7301-11
40. Adams JA, Taylor SS. 1992. Energetic limits of phosphotransfer in the catalytic subunit of cAMPdependent protein kinase as measured by viscosity experiments. Biochemistry 31:8516-22
41. Callaway K, Waas WF, Rainey MA, Ren P, Dalby KN. 2010. Phosphorylation of the transcription factor Ets-1 by ERK2: rapid dissociation of ADP and phospho-Ets-1. Biochemistry 49:3619-30
42. Cole PA, Grace MR, Phillips RS, Burn P, Walsh CT. 1995. The role of the catalytic base in the protein tyrosine kinase Csk. J. Biol. Chem. 270:22105-8
43. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, et al. 1995. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:313-20
44. Sicheri F, Moarefi I, Kuriyan J. 1997. Crystal structure of the Src family tyrosine kinase Hck. Nature 385:602-9
45. Xu W, Harrison SC, Eck MJ. 1997. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385:595-602
46. Cowan-Jacob SW, Fendrich G, Manley PW, JahnkeW, Fabbro D, et al. 2005. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13:861-71
47. Zheng J, KnightonDR, Ten Eyck LF, Karlsson R, XuongN, et al. 1993. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with magnesium-ATP and peptide inhibitor. Biochemistry 32:2154-61
48. Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ. 1994. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 367:704-11
49. LeiM, Robinson MA, Harrison SC. 2005. The active conformation of the PAK1 kinase domain. Structure 13:769-78
50. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, et al. 2006. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 281:33577-87
51. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, et al. 2003. Structure of a c-Kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278:31461-64
52. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. 2001. The TGFβ receptor activation process: an inhibitor-to substrate-binding switch. Mol. Cell 8:671-82
53. Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, et al. 2008. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134:793-803
54. Bayliss R, Sardon T, Vernos I, Conti E. 2003. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell 12:851-62
55. Pearce LR, Komander D, Alessi DR. 2010. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11:9-22
56. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. 2002. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 9:940-44
57. Grodsky N, Li Y, Bouzida D, Love R, Jensen J, et al. 2006. Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. Biochemistry 45:13970-81
58. Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T. 2006. Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure 14:589-600
59. Biondi RM, Komander D, Thomas CC, Lizcano JM, Deak M, et al. 2002. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J. 21:4219-28
60. Steinberg GR, Kemp BE. 2009. AMPK in health and disease. Physiol. Rev. 89:1025-78
61. Xiao B, HeathR, Saiu P, Leiper FC, Leone P, et al. 2007. Structural basis forAMPbinding to mammalian AMP-activated protein kinase. Nature 449:496-500
62. Townley R, Shapiro L. 2007. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science 315:1726-29
63. Amodeo GA, Rudolph MJ, Tong L. 2007. Crystal structure of the heterotrimer core of Saccharomyces cerevisiae AMPK homologue SNF1. Nature 449:492-95
64. Oakhill JS, Steel R, Chen ZP, Scott JW, LingN, et al. 2011.AMPKis a direct adenylate charge-regulated protein kinase. Science 332:1433-35
65. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, et al. 2011. Structure of mammalian AMPK and its regulation by ADP. Nature 472:230-33
66. Carling D, Mayer F, SandersM, Gamblin S. 2011. AMP-activated protein kinase: nature's energy sensor. Nat. Chem. Biol. 7:512-18
67. Zhu L, Chen L, Zhou XM, Zhang YY, Zhang YJ, et al. 2011. Structural insights into the architecture and allostery of full-length AMP-activated protein kinase. Structure 19:515-22
68. Chen L, Jiao ZH, Zheng LS, Zhang YY, Xie ST, et al. 2009. Structural insight into the autoinhibition mechanism of AMP-activated protein kinase. Nature 459:1146-49
69. Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141:1117-34
70. Hubbard SR, Wei L, Ellis L, Hendrickson WA. 1994. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372:746-54
71. Hubbard SR. 1997. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:5572-81
72. Mohammadi M, Schlessinger J, Hubbard SR. 1996. Structure of theFGFreceptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 86:577-87
73. Till JH, Becerra M, Watty A, Lu Y, Ma Y, et al. 2002. Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation. Structure 10:1187-96
74. Bergamin E, Hallock PT, Burden SJ, Hubbard SR. 2010. The cytoplasmic adaptor proteinDok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol. Cell 39:100-9
75. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. 2001. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106:745-57
76. Griffith J, Black J, Faerman C, Swenson L, WynnM, et al. 2004. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13:169-78
77. Shewchuk LM, Hassell AM, Ellis B, Holmes WD, Davis R, et al. 2000. Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 8:1105-13
78. Hubbard SR. 2004. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5:464-71
79. Oliver AW, Knapp S, Pearl LH. 2007. Activation segment exchange: a common mechanism of kinase autophosphorylation? Trends Biochem. Sci. 32:351-56
80. Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW, et al. 2006. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J. 25:3179-90
81. Xu YJ, Davenport M, Kelly TJ. 2006. Two-stage mechanism for activation of the DNA replication checkpoint kinase Cds1 in fission yeast. Genes Dev. 20:990-1003
82. Pike AC, Rellos P, Niesen FH, Turnbull A, Oliver AW, et al. 2008. Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J. 27:704-14
83. Bartek J, Lukas J. 2007. DNA damage checkpoints: from initiation to recovery or adaptation. Curr. Opin. Cell Biol. 19:238-45
84. Zhang K, Kaufman RJ. 2008. From endoplasmic-reticulum stress to the inflammatory response. Nature 454:455-62
85. Ali MM, Bagratuni T, Davenport EL, Nowak PR, Silva-SantistebanMC, et al. 2011. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 30:894-905
86. Lee KP, DeyM, Neculai D, Cao C, Dever TE, Sicheri F. 2008. Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell 132:89-100
87. Korennykh AV, Egea PF, Korostelev AA, Finer-Moore J, Zhang C, et al. 2009. The unfolded protein response signals through high-order assembly of Ire1. Nature 457:687-93
88. Wiseman RL, Zhang Y, Lee KP, Harding HP, Haynes CM, et al. 2010. Flavonol activation defines an unanticipated ligand-binding site in the kinase-RNase domain of IRE1. Mol. Cell 38:291-304
89. Papa FR, Zhang C, Shokat K, Walter P. 2003. Bypassing a kinase activity with an ATP-competitive drug. Science 302:1533-37
90. Ferguson KM. 2008. Structure-based view of epidermal growth factor receptor regulation. Annu. Rev. Biophys. 37:353-73
91. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. 2010. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 107:7692-97
92. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. 2009. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. USA 106:21608-13
93. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, et al. 2009. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol. Cell 34:641-51
94. Jura N, Endres NF, Engel K, Deindl S, Das R, et al. 2009. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137:1293-307
95. Stamos J, Sliwkowski MX, Eigenbrot C. 2002. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:46265-72
96. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, et al. 2011. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J. Biol. Chem. 286:18756-65
97. Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, et al. 2008. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16:460-67
98. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-49
99. Monsey J, ShenW, Schlesinger P, Bose R. 2010. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J. Biol. Chem. 285:7035-44
100. Claperon A, Therrien M. 2007. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 26:3143-58
101. Kolch W. 2005. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6:827-37
102. Udell CM, Rajakulendran T, Sicheri F, Therrien M. 2011. Mechanistic principles of RAF kinase signaling. Cell Mol. Life Sci. 68:553-65
103. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67
104. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. 2008. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105:3041-46
105. Hansen JD, Grina J, Newhouse B, Welch M, TopalovG, et al. 2008. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett. 18:4692-95
106. King AJ, Patrick DR, Batorsky RS, Ho ML, DoHT, et al. 2006. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66:11100-5
107. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M. 2009. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461:542-45
108. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, et al. 2011. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472:366-69
109. Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, et al. 2011. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl. Acad. Sci. USA 108:6067-72
110. Poulikakos PI, Zhang C, Bollag G, ShokatKM, RosenN. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30
111. McKay MM, Ritt DA, Morrison DK. 2011. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr. Biol. 21:563-68
112. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. 2006. Emerging roles of pseudokinases. Trends Cell Biol. 16:443-52
113. Zeqiraj E, Van Aalten DM. 2010. Pseudokinases-remnants of evolution or key allosteric regulators? Curr. Opin. Struct. Biol. 20:772-81
114. Min X, Lee BH, Cobb MH, Goldsmith EJ. 2004. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 12:1303-11
115. Mayans O, Van der Ven PF, Wilm M, Mues A, Young P, et al. 1998. Structural basis for activation of the titin kinase domain during myofibrillogenesis. Nature 395:863-69
116. Mukherjee K, Sharma M, Urlaub H, Bourenkov GP, Jahn R, et al. 2008. CASK functions as a Mg2+-independent neurexin kinase. Cell 133:328-39
117. Alessi DR, Sakamoto K, Bayascas JR. 2006. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 75:137-63
118. Zeqiraj E, Filippi BM, Deak M, Alessi DR, Van Aalten DM.2009. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326:1707-11
119. Saharinen P, Vihinen M, Silvennoinen O. 2003. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14:1448-59
120. Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, et al. 2011. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS ONE 6:e18522
121. Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, et al. 2011. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18:971-76
122. Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, et al. 2010. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol. 400:413-33
123. Fukuda K, Gupta S, Chen K, Wu C, Qin J. 2009. The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. Mol. Cell 36:819-30
124. Fukuda K, Knight JD, Piszczek G, Kothary R, Qin J. 2011. Biochemical, proteomic, structural, and thermodynamic characterizations of integrin-linked kinase (ILK): cross-validation of the pseudokinase. J. Biol. Chem. 286:21886-95
125. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. 2009. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17:128-38
126. Good MC, Zalatan JG, Lim WA. 2011. Scaffold proteins: hubs for controlling the flow of cellular information. Science 332:680-86
127. Schwartz MA, Madhani HD. 2004. Principles of MAP kinase signaling specificity in Saccharomyces cerevisiae. Annu. Rev. Genet. 38:725-48
128. Good M, Tang G, Singleton J, Remenyi A, Lim WA. 2009. The Ste5 scaffold directs mating signaling by catalytically unlocking the Fus3 MAP kinase for activation. Cell 136:1085-97
129. Leonard TA, Rozycki B, Saidi LF, Hummer G, Hurley JH. 2011. Crystal structure and allosteric activation of protein kinase C betaII. Cell 144:55-66
130. Chao LH, Pellicena P, Deindl S, Barclay LA, Schulman H, Kuriyan J. 2010. Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation. Nat. Struct. Mol. Biol. 17:264-72
131. Rellos P, Pike AC, Niesen FH, Salah E, LeeWH, et al. 2010. Structure of the CaMKIIdelta/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. PLoS Biol. 8:e1000426
132. Chao LH, Stratton MM, Lee IH, Rosenberg OS, Levitz J, et al. 2011. A mechanism for tunable autoinhibition in the structure of a human Ca2 +calmodulin-dependent kinase II holoenzyme. Cell 146:732-45
133. Liu D, Vader G, Vromans MJ, Lampson MA, Lens SM. 2009. Sensing chromosome bi-orientation by spatial separation of Aurora B kinase from kinetochore substrates. Science 323:1350-53
134. Welburn JP, VleugelM, Liu D, Yates JR3rd, LampsonMA, et al. 2010. AuroraBphosphorylates spatially distinct targets to differentially regulate the kinetochore-microtubule interface. Mol. Cell 38:383-92
135. Xu Z, Vagnarelli P, OgawaH, SamejimaK, EarnshawWC. 2010. Gradient of increasing Aurora B kinase activity is required for cells to execute mitosis. J. Biol. Chem. 285:40163-70
136. Alexander J, Lim D, Joughin BA, Hegemann B, Hutchins JR, et al. 2011. Spatial exclusivity combined with positive and negative selection of phosphorylation motifs is the basis for context-dependent mitotic signaling. Sci. Signal. 4:ra42
137. Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R. 1993. Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 ?A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J. 12:849-59
138. Knighton DR, Zheng JH, Ten Eyck LF, Xuong NH, Taylor SS, Sowadski JM. 1991. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253:414-20
139. Brown NR, Noble ME, Endicott JA, Johnson LN. 1999. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1:438-43